原来心真会“碎”，心碎综合征是种什么病？
High stress may make ‘broken heart syndrome’ more likely, study finds

The syndrome, formally known as takotsubo cardiomyopathy, is characterized by weakening of the heart’s main pumping chamber and was first identified in 1990 in Japan. It looks and sounds like a heart attack and is consequently often confused for one.心碎综合征学名为takotsubo心肌病，最早于1990年在日本被发现，其特征是心脏的主泵区功能减弱。症状与心脏病相似，因此经常被混淆。

Notes:

Two molecules – called microRNA-16 and microRNA-26a — that are linked to depression, anxiety and increased stress levels had previously been detected in the blood of takotsubo patients. Researchers assessed the impact of exposing cells from human hearts (taken from organs that were unsuitable for transplants) and rat hearts to the two molecules.此前在心碎综合征患者的血液中检测到两种名为微小核糖核酸-16和微小核糖核酸-26a的分子，这两种分子与抑郁、焦虑和压力水平升高有关。研究人员评估了将人类心脏（取自不适合移植的器官）和大鼠心脏的细胞暴露于这两种分子的影响。

In patients with takotsubo, the bottom of the heart stops beating, and the top of the heart beats more, said the lead study author, Dr Liam Couch from Imperial College London. “Basically, we found the exact same thing happens when we increase the exposure to the molecules [in an experimental setting]. It reproduced exactly what happens in takotsubo, so it made it more likely for the takotsubo to occur.”该研究的主要作者、伦敦帝国理工学院的利亚姆·考奇博士称，心碎综合征患者的心脏底部停止跳动，顶部跳动更多。“基本上，我们发现（在实验环境中）当我们增加心脏对这两种分子的暴露时，会发生完全相同的情况。它准确地再现了心碎综合征发生的情况，因此使心碎综合征发生的可能性更大。”

However, the problem is that it is not possible, for now, to diagnose takotsubo in patients before it happens, making it difficult to test whether these molecules are elevated in real-life cases, Couch explained.然而，考奇解释称，问题是，目前还不能在心碎综合征发生之前对患者进行诊断，这使得在现实中很难检测这些分子是否升高。

Joel Rose, chief executive of the charity Cardiomyopathy UK, said the study provided important insights on a less well known and poorly understood form of cardiomyopathy. “It has the potential to improve our understanding of who may be more susceptible to developing the condition and subsequent improve our ability to manage its impact,” he said.慈善机构“英国心肌病（Cardiomyopathy UK）”首席执行官乔尔·罗斯称，这项研究对一种鲜为人知、缺乏了解的心肌病提供了重要见解，有可能提高我们对这种疾病易见于哪些人群的认识，进而增强我们控制其影响的能力。”